All News Novartis AG

Equities

Real-time Estimate Cboe Europe Other stock markets 06:00:28 2024-04-23 am EDT			5-day change	1st Jan Change
91.75 ^CHF	+5.03%		+7.85%	+8.01%

11:35am	NOVARTIS AG : UBS remains its Buy rating	ZD
11:29am	Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	MT

NOVARTIS AG : UBS remains its Buy rating	05:35am	ZD
Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	05:29am	MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	05:12am	MT
Novartis: Q1 Earnings Snapshot	05:04am	AQ
NOVARTIS AG : Gets a Buy rating from Jefferies	04:47am	ZD
Novartis Raises Guidance on Profit, Sales Growth -- Update	04:33am	DJ
Novartis raises targets for 2024	03:21am	CF
CAC 40: slight upturn in optimism ahead of PMIs	02:38am	CF
Switzerland's Novartis Logs Improved Q1 Net Income, Sales	01:47am	MT
Novartis Raises Guidance on Profit, Sales Growth	01:40am	DJ
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised	01:00am	GL
EMEA Morning Briefing : Shares Set to Rise as Geopolitical Concerns Ease	12:18am	DJ
Novartis AG Reports Earnings Results for the First Quarter Ended March 31, 2024	10:07pm	CI
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
NOVARTIS AG : UBS reiterates its Buy rating	Apr. 18	ZD
TotalEnergies: shareholders want to separate powers	Apr. 18	CF
NOVARTIS AG : Deutsche Bank maintains a Buy rating	Apr. 18	ZD
Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years	Apr. 17	MT
Novartis: positive efficacy data in MS	Apr. 17	CF
Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	Apr. 17	DJ

No results for this search

NOVARTIS : Novartis on course to set new highs

February 20, 2024 at 11:30 am EST

Novartis AG : Sandoz takes its first steps on the stock exchange